Study Summary
To evaluate the safety and tolerability of Human CD19-CD22 Targeted T Cells Injection for the treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19-CD22 CAR+ T cells.
Want to learn more about this trial?
Request More InfoInterventions
Human CD19-CD22 Targeted T Cells InjectionDRUG
One time single predetermined dose level CAR-positive T cells will be utilized based on the NMPA approved product label.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | Shanghai Municipality | China |